Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Brain Neoplasms 4Breast Neoplasms 3Recurrence 2Glioblastoma 2Triple Negative Breast Neoplasms 1Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Glioma 1Carcinoma, Hepatocellular 1Astrocytoma 1

Interventions

Temozolomide 203Radiotherapy 118Bevacizumab 93Radiation 40Magnetic Resonance Spectroscopy 28Irinotecan 27Carmustine 25Surgical Procedures, Operative 24Lomustine 21Erlotinib Hydrochloride 19Chemotherapy, Adjuvant 18Carboplatin 17temsirolimus 13Drug Therapy 13O(6)-benzylguanine 12Nivolumab 12sargramostim 11Sirolimus 11Radiotherapy, Intensity-Modulated 11Radiotherapy, Conformal 11Sorafenib 10Radiosurgery 10Imatinib Mesylate 10Everolimus 10pembrolizumab 9motexafin gadolinium 9Vorinostat 9Thalidomide 8IL13-PE38 8Gefitinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Glioblastoma × paclitaxel-Angiopep-2 conjugate × Clear all
NCT01967810 2020-02-25

ANG1005 in Patients With Recurrent High-Grade Glioma

Angiochem Inc

Phase 2 Completed
73 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Recurrence

NCT00539344 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Angiochem Inc

Phase 1 Completed
63 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡